199456-59-2

Upstream product

• 58677-06-8 2-isobutyrylamino-6-methyl-3H-quinazolin-4-one 
• 106918-32-5 4-carbomethoxyphenylacetaldehyde 
• 58677-07-9 N-[6-(bromomethyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2,2-dimethylpropanamide 
• 199456-58-1 4-[2-(Dimethyl-hydrazono)-ethyl]-benzoic acid methyl ester 

Downstream Products

• 199456-60-5 4-[2-(2-Amino-4-oxo-3,4-dihydro-quinazolin-6-yl)-1-(dimethyl-hydrazonomethyl)-ethyl]-benzoic acid 
• 182217-62-5 6-[2'-Formyl-2'-(4-carbomethoxy phenyl)-ethyl]-2-pivaloylamino-4(3H)-oxo-quinazoline 
• 199456-61-6 (S)-2-{4-[2-(2-Amino-4-oxo-3,4-dihydro-quinazolin-6-yl)-1-(dimethyl-hydrazonomethyl)-ethyl]-benzoylamino}-pentanedioic acid di-tert-butyl ester 
• 199456-70-7 (S)-2-{4-[2-(2-Amino-4-oxo-3,4-dihydro-quinazolin-6-yl)-acetyl]-benzoylamino}-pentanedioic acid di-tert-butyl ester 
• 199456-62-7 (S)-2-{4-[2-(2-Amino-4-oxo-3,4-dihydro-quinazolin-6-yl)-1-(dimethyl-hydrazonomethyl)-ethyl]-benzoylamino}-pentanedioic acid dimethyl ester 
• 145298-15-3 (S)-2-{4-[2-(2-Amino-4-oxo-3,4-dihydro-quinazolin-6-yl)-1-formyl-ethyl]-benzoylamino}-pentanedioic acid di-tert-butyl ester 
• 199456-63-8 (S)-2-{4-[2-(2-Amino-4-oxo-3,4-dihydro-quinazolin-6-yl)-1-formyl-ethyl]-benzoylamino}-pentanedioic acid dimethyl ester 
• 199456-65-0 4-[2-(2-Amino-4-oxo-3,4-dihydro-quinazolin-6-yl)-1-(dimethyl-hydrazonomethyl)-ethyl]-benzoic acid methyl ester 
• 182217-65-8 6-[2'-Formyl-2'-(4-carbomethoxy phenyl)-ethyl]-2-amino-4(3H)-oxoquinazoline 

Relevant academic research and scientific papers

10-Formyl-5,8,10-trideazafolic acid (10-formyl-TDAF): A potent inhibitor of glycinamide ribonucleotide transformylase

The synthesis of 10-formyl-5,8,10-trideazafolic acid (3) as a potential inhibitor of glycinamide ribonucleotide transformylase (GAR Tfase) is reported. The target compound was prepared by a convergent synthesis utilizing the alkylation of hydrazone 5 with benzylic bromide 6 to construct the core heterocycle 7. The aldehyde 3 and related agents were evaluated as inhibitors of purN GAR Tfase and avian AICAR Tfase. Compound 3 exhibited potent inhibition of GAR Tfase with a K(i) of 0.26 ± 0.05 μM. In contrast, 3 exhibited more moderate inhibition of aminoimidazole carboxamide ribonucleotide transformylase (AICAR Tfase), with K(i) of 7.6 ± 1.5 μM.